長陽科技(688299.SH):與東麗簽署合作協議
格隆匯 11 月 3日丨長陽科技(688299.SH)公佈,東麗和公司一致同意撤回光反射板用白色聚酯膜相關專利的未決爭議、加強合作,實現共贏,公司也有意向從東麗獲得東麗合法擁有的中國專利CN200780040088.8(專利發明名稱:光反射板用白色聚酯膜,“本專利”)的許可,東麗願意基於本協議的條件將本專利的許可授予長陽,經雙方一致協商,於近日共同簽署了《合作協議》,合作協議自簽署日生效。
東麗株式會社,創立於1926年1月,註冊地址為日本東京中央區日本橋室町2丁目1-1,103-8666,主要製造、加工和銷售產品包括纖維和紡織品、高性能化學品、碳纖維複合材料等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.